Protalix Biotherapeutics Inc Share Price TEL AVIV STOCK EXCHANGE
Stocks
US74365A1016
Pharmaceuticals
| Market Cap | 22Cr 0 19Cr 18Cr 17Cr 31Cr 2.1TCr 31Cr 217.35Cr 84Cr 1.07TCr 82Cr 81Cr 3.45TCr | P/E 2026 * |
11.3x | P/E 2027 * | 54.4x |
|---|---|---|---|---|---|
| Enterprise Value | 22Cr 0 19Cr 18Cr 17Cr 31Cr 2.1TCr 31Cr 217.35Cr 84Cr 1.07TCr 82Cr 81Cr 3.45TCr | EV / Sales 2026 * |
2.67x | EV / Sales 2027 * | 3.3x |
| Free-Float |
96.12% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Protalix Biotherapeutics Inc
| 1 day | -1.13% |
| Manager | Title | Age | Since |
|---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 59 | 30/06/2019 |
Gilad Mamlok
DFI | Director of Finance/CFO | 57 | 24/08/2025 |
Ori Kalid
CTO | Chief Tech/Sci/R&D Officer | - | 01/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Amos Bar Shalev
BRD | Director/Board Member | 73 | 01/07/2008 |
Aharon Schwartz
BRD | Director/Board Member | 83 | 01/11/2014 |
Dror Bashan
BRD | Director/Board Member | 59 | 30/06/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.13% | -11.89% | - | - | 22Cr | |
| +0.13% | +2.65% | +65.61% | +114.28% | 1,05500Cr | |
| +0.20% | +0.46% | +52.60% | +69.24% | 65TCr | |
| -0.29% | +0.14% | +20.96% | +70.93% | 47TCr | |
| -0.85% | +0.98% | +41.29% | +44.38% | 35TCr | |
| +0.71% | +4.08% | +22.24% | +29.51% | 27TCr | |
| +1.23% | +0.42% | +14.57% | +12.13% | 26TCr | |
| +2.11% | +7.51% | +52.89% | +55.37% | 22TCr | |
| +0.83% | +0.55% | +35.99% | +101.70% | 19TCr | |
| 0.00% | -10.14% | -29.94% | -60.30% | 17TCr | |
| Average | +0.21% | +0.74% | +30.69% | +48.58% | 40.43TCr | |
| Weighted average by Cap. | +0.02% | +1.32% | +41.54% | +67.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.22Cr 0 7.21Cr 6.81Cr 6.21Cr 12Cr 787.44Cr 12Cr 81Cr 32Cr 402.29Cr 31Cr 30Cr 1.29TCr | 6.65Cr 0 5.83Cr 5.51Cr 5.02Cr 9.4Cr 637.17Cr 9.47Cr 66Cr 26Cr 325.52Cr 25Cr 24Cr 1.05TCr |
| Net income | 1.96Cr 0 1.72Cr 1.63Cr 1.48Cr 2.78Cr 188.16Cr 2.8Cr 19Cr 7.54Cr 96Cr 7.37Cr 7.21Cr 308.94Cr | 37.94L 0 33.29L 31.44L 28.65L 53.64L 36Cr 54.02L 3.76Cr 1.46Cr 19Cr 1.42Cr 1.39Cr 60Cr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
